**Author Information** An event is serious (FDA MedWatch definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* requires intervention to prevent permanent impairment or damage

A 69-year-old man developed jaundice, hyperbilirubinaemia and renal failure \[*outcomes not stated*\] during treatment with ribavirin.

The man was diagnosed with Middle East respiratory syndrome coronavirus (MERS-CoV) infection and started on an empirical antiviral regimen on day 13 of the illness. The regimen consisted of oral ribavirin 2000mg loading dose, followed by 1200mg every 8 hours for 8 days, along with lopinavir/ritonavir and peginterferon \[pegylated interferon\]. On day 16 of the illness, he was diagnosed with acute kidney injury. He remained febrile with a maximum value of 40.5°C on day 18 of the illness. On day 19, there was normalisation of the bowel movements and gastrointestinal function. He developed jaundice and hyperbilirubinaemia which were attributed to ribavirin.

Hence, on day 20, ribavirin was was discontinued. The man\'s acute kidney injury rapidly progressed to non-oliguric renal failure that reverted to RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) injury level on day 21. Two months and 19 days after the initial diagnosis, he eventually died due to septic shock.

**Author comment:** *\"Owing to development of jaundice and hyperbilirubinaemia attributed to ribavirin, the drug was discontinued on Day 20.\" \"The possibility that \[ribavirin\] toxicity might have contributed in the renal dysfunction could not be excluded\".*
